A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid
synthesis and transport. Bile acids are used by the body to help with digestion. It is
hypothesized that regular treatment with TQA3526 will improve liver function in persons with
Primary Biliary Cirrhosis (PBC).